Tamiflu Harms

Tagged: 

  • Tamiflu Harms

    Posted by IMA-HelenT on August 26, 2026 at 4:23 pm EDT

    New Evidence of Harm from Tamiflu in Critically Ill Patients Underscores Why Science Is Rarely “Settled”

    Approved more than two decades ago and generating roughly $20 billion in sales, Tamiflu never underwent rigorous randomized trials in the sickest patients until now; results show potential increased mortality.

    “This is a clear reminder that science is not always settled, and ongoing discussion and sharing of observations among doctors should always be encouraged,” said IMA President and Chief Medical Officer Dr. Joseph Varon. “Tamiflu has been on the market for more than 25 years and has generated $20 billion in sales. Yet until now, we never had a proper randomized trial in the patients who are the sickest. The results suggest the drug may actually be hurting them.”

    Read the full IMA statement: https://imahealth.org/new-evidence-of-harm-from-tamiflu-in-critically-ill-patients-underscores-why-science-is-rarely-settled/

    IMA-HelenT replied 12 minutes ago 3 Members · 4 Replies
  • 4 Replies
  • vegandan

    Member
    August 26, 2026 at 6:21 pm EDT

    Years ago didn’t the Federal Government purchase millions of doses of Tamiflu for a “just in case” pandemic? I’m thinking this was another windfall for the drug manufacturer at the taxpayer’s expense. Who among us is willing to take a defective product in the hopes that it will be more helpful than harmful?

    • IMA-HelenT

      Organizer
      August 27, 2026 at 5:33 am EDT

      💯 <div>


      By the end of 2009 around 95 governments had reportedly purchased or ordered pandemic Tamiflu stocks.

      Roche said it supplied governments with around 350 million treatment courses, 3.5 billion individual doses, between 2004 and 2009. Estimates put global government spending on stockpiling at billions of dollars.

      Then in 2010 Attention increasingly turned to whether the evidence supporting such enormous purchases had been strong enough. The BMJ and Cochrane pursued access to previously unavailable clinical-study reports, ultimately raising questions about some of the claims that had helped justify stockpiling, particularly around reducing serious influenza complications.

      An astonishing waste of our money and more!

      </div>

  • dickatlee

    Member
    August 26, 2026 at 8:35 pm EDT

    It’s odd that so often IMA pieces refer to studies without providing links to them. Luckily, Steve Kirsch reposted Alex Berensen’s long piece on it, which linked to the study:

    https://papers.ssrn.com/sol3/papers.cfm?abstract_id=7172531

    Berensen’s piece is at

    https://alexberenson.substack.com/p/urgent-tamiflu-kills

    (Oddly, when I clicked on the email link from the forum to discuss it in the forum, I wound up in a “Beta” version of it, acting as if the forum was brand new. Strange.)

    • IMA-HelenT

      Organizer
      August 27, 2026 at 5:34 am EDT

      Thanks for that feedback…. going to feed it back to the team.

Log in to reply.